Flexible Administration of COVID-19 Vaccines and Therapeutics—A Call for Clarity Around Legality, Liability, and Compensation for Injury
Document Type
Article
Year
2022
Citation Information
Govind Persad; Patricia Zettler; and Holly Fernandez Lynch JD, MBE, Flexible Administration of COVID-19 Vaccines and Therapeutics—A Call for Clarity Around Legality, Liability, and Compensation for Injury, (2022), available at https://scholar.law.colorado.edu/faculty-articles/2000.
Abstract
Over the past two years, the Food and Drug Administration (FDA) has approved or issued emergency use authorizations (EUAs) for several interventions intended to prevent or treat COVID-19, including vaccines, monoclonal antibodies, and antiviral medications. These approvals and EUAs are for specific indications, in specific populations, at specific doses, and on specific dosing schedules. However, individuals, clinicians, and state and local governments have often expressed interest in using these COVID-19 interventions outside the parameters specifically approved or authorized by the FDA.